Literature DB >> 28320834

Early Intracellular Trafficking of Granulibacter bethesdensis in Human Macrophages.

Jessica Chu1, Margery G Smelkinson2, David W Dorward3, Kol A Zarember1, John I Gallin4.   

Abstract

Granulibacter bethesdensis is a Gram-negative bacterium that infects patients with chronic granulomatous disease (CGD), a primary immunodeficiency marked by a defect in NOX2, the phagocyte NADPH oxidase. Previous studies have shown that NOX2 is essential for killing of G. bethesdensis by neutrophils and monocytes and that the bacteriostatic activity of monocyte-derived macrophages (MDM) requires NOX2 and gamma interferon (IFN-γ) pretreatment. To determine whether G. bethesdensis evades phagolysosomal killing, a host defense pathway intact in both normal and CGD MDM, or whether it occupies a distinct intracellular niche in CGD MDM, we assessed the trafficking patterns of this organism. We observed colocalization of G. bethesdensis with an early endosome antigen 1 (EEA1)-positive compartment, followed by colocalization with lysosome-associated membrane protein 1 (LAMP1)-positive and LysoTracker-positive late phagosomes; these characteristics were similar in both normal and CGD MDM. Despite localization to acidified late phagosomes, viable G. bethesdensis cells were recovered from viable MDM in numbers greater than in the initial input up to 6 days after infection. G. bethesdensis remains, and in some cases appears to divide, within a membrane-bound compartment for the entire 6-day time course. These findings indicate that this organism resists both oxygen-dependent and oxygen-independent phagolysosomal antimicrobial systems of human macrophages.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Gram-negative bacteria; Granulibacter; chronic granulomatous disease; innate immunity; macrophages; microbial pathogenesis; vesicular trafficking

Mesh:

Substances:

Year:  2017        PMID: 28320834      PMCID: PMC5442635          DOI: 10.1128/IAI.00847-16

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

Review 1.  Actin-based motility of intracellular pathogens.

Authors:  Edith Gouin; Matthew D Welch; Pascale Cossart
Journal:  Curr Opin Microbiol       Date:  2005-02       Impact factor: 7.934

Review 2.  Acid resistance in Mycobacterium tuberculosis.

Authors:  Omar H Vandal; Carl F Nathan; Sabine Ehrt
Journal:  J Bacteriol       Date:  2009-05-22       Impact factor: 3.490

Review 3.  Antimicrobial mechanisms of phagocytes and bacterial evasion strategies.

Authors:  Ronald S Flannagan; Gabriela Cosío; Sergio Grinstein
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

4.  Intracellular trafficking of Bordetella pertussis in human macrophages.

Authors:  Yanina A Lamberti; Jimena Alvarez Hayes; Maria L Perez Vidakovics; Eric T Harvill; Maria Eugenia Rodriguez
Journal:  Infect Immun       Date:  2010-01-11       Impact factor: 3.441

5.  Innate immunity against Granulibacter bethesdensis, an emerging gram-negative bacterial pathogen.

Authors:  Kol A Zarember; Kimberly R Marshall-Batty; Anna R Cruz; Jessica Chu; Michael E Fenster; Adam R Shoffner; Larissa S Rogge; Adeline R Whitney; Meggan Czapiga; Helen H Song; Pamela A Shaw; Kunio Nagashima; Harry L Malech; Frank R DeLeo; Steven M Holland; John I Gallin; David E Greenberg
Journal:  Infect Immun       Date:  2011-12-19       Impact factor: 3.441

6.  Gluconobacter as well as Asaia species, newly emerging opportunistic human pathogens among acetic acid bacteria.

Authors:  Corentine Alauzet; Corinne Teyssier; Estelle Jumas-Bilak; Anne Gouby; Raphael Chiron; Christian Rabaud; François Counil; Alain Lozniewski; Hélène Marchandin
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

7.  Acidomonas methanolica-associated necrotizing lymphadenitis in a patient with chronic granulomatous disease.

Authors:  John M Chase; Steven M Holland; David E Greenberg; Kimberly Marshall-Batty; Adrian M Zelazny; Joseph A Church
Journal:  J Clin Immunol       Date:  2012-06-30       Impact factor: 8.317

8.  The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression.

Authors:  Audrey Chong; Tara D Wehrly; Vinod Nair; Elizabeth R Fischer; Jeffrey R Barker; Karl E Klose; Jean Celli
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

9.  Lysis and killing of bacteria by lysosomal proteinases.

Authors:  K J Thorne; R C Oliver; A J Barrett
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

10.  A three-dimensional comparison of tick-borne flavivirus infection in mammalian and tick cell lines.

Authors:  Danielle K Offerdahl; David W Dorward; Bryan T Hansen; Marshall E Bloom
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more
  3 in total

1.  Fulminant Sepsis Due to Granulibacter bethesdensis in a 4-Year-Old Boy With X-Linked Chronic Granulomatous Disease.

Authors:  Erick F Mayer; Philip Gialanella; Iona Munjal; Charlotte Cunningham-Rundles; Jasmeen Dara
Journal:  Pediatr Infect Dis J       Date:  2017-12       Impact factor: 2.129

2.  Phagocytosis by endothelial cells inhibits procoagulant activity of platelets of essential thrombocythemia in vitro.

Authors:  Shuting Ji; Weijun Dong; Yushan Qi; Hong Gao; Danwei Zhao; Minghui Xu; Tingting Li; Hongyin Yu; Yuting Sun; Ruishuang Ma; Jialan Shi; Chunyan Gao
Journal:  J Thromb Haemost       Date:  2019-09-10       Impact factor: 5.824

3.  Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid-Lipid A Glycolipid (Ko-Lipid A).

Authors:  Artur Muszyński; Kol A Zarember; Christian Heiss; Joseph Shiloach; Lars J Berg; John Audley; Arina Kozyr; David E Greenberg; Steven M Holland; Harry L Malech; Parastoo Azadi; Russell W Carlson; John I Gallin
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.